Report Overview

The Brazil Glioma Therapeutics market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

GBMs are biologically aggressive tumors that present unique treatment challenges due to the localization of tumors in the brain, inherent resistance to conventional therapy, limited capacity of the brain to repair itself, migration of malignant cells into adjacent brain tissue, the variably disrupted tumor blood supply which inhibits effective drug delivery, tumor capillary leakage, resulting in an accumulation of fluid around the tumor and they have a limited response to therapy. The mainstay of treatment for GBMs is surgery, followed by radiation and chemotherapy.



Market Drivers

Increasing burden of brain disorders among younger and elder population of the country, strong R&D initiatives from key players and rising geriatric population are boosting the growth of the glioma treatment market. The growing focus toward the development of better treatment options invites more cancer chemotherapy-based companies to generate innovative drugs as well as explore different geographic regions to grow the sales of chemotherapy and radiation therapy products thus fuelling the growth of glioma treatment market.